Anixa Biosciences Inc (ANIX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 10/31
| 04-2022 | 01-2022 | 10-2021 | 07-2021 | 04-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 27,732 | 29,781 | 29,128 | 27,222 | 27,703 |
| Marketable Securities | 4,499 | 4,749 | 6,599 | 9,400 | 10,399 |
| TOTAL | $32,563 | $34,994 | $36,003 | $37,052 | $38,472 |
| Non-Current Assets | |||||
| Other Non-Current Assets | 234 | 244 | 254 | 10 | 26 |
| TOTAL | $234 | $244 | $254 | $10 | $26 |
| Total Assets | $32,797 | $35,238 | $36,257 | $37,062 | $38,498 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 93 | 504 | 136 | 208 | 438 |
| Accrued Expenses | 1,057 | 1,242 | 1,095 | 990 | 979 |
| TOTAL | $1,189 | $1,787 | $1,270 | $1,208 | $1,443 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 246 | 259 | 278 | 54 | 38 |
| TOTAL | $202 | $209 | $220 | $N/A | $N/A |
| Total Liabilities | $1,391 | $1,996 | $1,490 | $1,208 | $1,443 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 30,471 | 30,152 | 30,132 | 29,950 | 29,950 |
| Common Shares | 302 | 301 | 301 | 300 | 315 |
| Retained earnings | -212,163 | -208,619 | -204,790 | -200,777 | -196,443 |
| Other shareholders' equity | -765 | -721 | -671 | -613 | -559 |
| TOTAL | $31,406 | $33,242 | $34,767 | $35,854 | $37,055 |
| Total Liabilities And Equity | $32,797 | $35,238 | $36,257 | $37,062 | $38,498 |